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Dual Role of Apoptosis-Associated Speck-Like
Protein Containing a CARD (ASC) in Tumorigenesis
of Human Melanoma
Weimin Liu1, Yuchun Luo1, Jeffrey H. Dunn1, David A. Norris1,2, Charles A. Dinarello3 and Mayumi Fujita1,2
Apoptosis-associated Speck-like protein containing a CARD (caspase recruitment domain) (ASC) was originally
named because it triggered apoptosis in certain tumors. More recently, however, ASC was found to be a central
adaptor protein of inflammasome, which mediates the secretion of protumorigenic inflammation. Here we
examined the role of ASC in tumorigenesis of human melanoma. Compared with primary melanoma, ASC
protein expression was generally downregulated in metastatic melanoma. Although overexpressing ASC in
metastatic melanoma showed no effects on cell viability, silencing ASC with short hairpin RNA induced G1 cell
cycle arrest, reduced cell viability, and suppressed tumorigenesis in metastatic melanoma. On the other hand,
silencing ASC in primary melanoma reduced cell death, increased cell viability, and enhanced tumorigenesis. In
primary and metastatic melanoma cells, ASC knockdown inhibited inflammasome-mediated caspase-1 activity
and IL-1b secretion. However, phosphorylated IkB kinase (IKK)a/b expression and NF-kB activity were
suppressed in metastatic melanoma and enhanced in primary melanoma after ASC knockdown. These findings
suggest stage-dependent dual roles of ASC in tumorigenesis. ASC expression in primary melanoma inhibits
tumorigenesis by reducing IKKa/b phosphorylation and inhibiting NF-kB activity. In metastatic melanoma, on
the other hand, this inhibitory effect is diminished, and ASC induces tumorigenic pathways through enhanced
NF-kB activity and inflammasome-mediated IL-1b secretion.
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INTRODUCTION
ASC (Apoptosis-associated Speck-like protein containing a CARD,
caspase recruitment domain) was originally named because it
induced apoptosis when overexpressed in HL-60 human
leukemia cells (Masumoto et al., 1999). ASC facilitates transloca-
tion of Bax to mitochondria, and increases mitochondrial
permeability, cytochrome c release, and activation of caspase-9
and caspase-3 (McConnell and Vertino, 2004; Ohtsuka et al.,
2004). ASC is also called TMS1 (Target of Methylation-mediated
Silencing) because ASC expression is suppressed in many human
tumors by methylation of CpG islands in the ASC gene, which
likely prevents cancer cells from undergoing apoptosis (Conway
et al., 2000; Stone et al., 2004; Das et al., 2006). These data
suggest a tumor suppressor role of ASC.
Structurally, ASC contains an N-terminal pyrin domain
(PYD) and a C-terminal CARD (Martinon et al., 2002). ASC is
highly expressed in immune cells, particularly in neutrophils
and monocytes. As a central adaptor protein of inflammasome,
ASC was recently found to mediate inflammatory signals by
recruiting CARD-containing pro-caspase-1 to several PYD-
containing NOD-like receptors (NLRs), including NLR family
containing PYD (NLRP)3. ASC thus has a pivotal role in the
caspase-1-dependent processing of proinflammatory cytokines
such as IL-1b. Because IL-1b is a pleiotropic proinflammatory
cytokine involved in cell growth, differentiation, tissue repair,
and regulation of immune response (Dinarello, 2009), tumor
cells secreting IL-1b have a greater propensity for invasion,
angiogenesis, antitumor suppression, and metastasis (Song
et al., 2003, 2005), and IL-1b is strongly implicated in tumor
progression (Dinarello, 2010; Okamoto et al., 2010). We have
previously shown that the NLRP3 inflammasome (composed of
NLRP3, ASC, and pro-caspase-1) is constitutively assembled
and activated in human melanoma cells, resulting in
spontaneous IL-1b secretion in metastatic melanoma cells
(Okamoto et al., 2010). These results suggest a tumor-
promoting role of ASC in human melanoma.
In this study, we examined the role of ASC in melanoma-
genesis using primary and metastatic human melanoma cell
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lines. We provide evidence that ASC has stage-dependent
dual roles in tumorigenesis by differentially regulating NF-kB
activity and IL-1b secretion in human melanoma cells.
RESULTS
ASC expression is downregulated in metastatic melanoma
We analyzed 12 human melanoma tumor specimens (six
primary and six metastatic melanoma tumors) for ASC
expression. Consistent with a published report (Guan et al.,
2003), ASC was highly expressed in normal melanocytes
(Supplementary Figure 1 online) and suppressed in human
melanoma tissues. There was a trend of ASC to a further
reduction in metastatic melanoma compared with primary
melanoma (Figure 1a and Supplementary Table 1). We then
analyzed ASC expression in 10 human melanoma cell lines
(five primary and five metastatic lines). Western blot analysis
showed reduced ASC expression in most metastatic melano-
ma cell lines (Figure 1b). To investigate expression-dependent
and/or stage-dependent roles of ASC in human melanoma,
we used two primary melanoma cells, WM35 and WM115,
expressing relatively higher (WM35) and lower (WM115)
ASC among primary cells, and two metastatic melanoma
cells, HS294T and 1205Lu, expressing higher (HS294T) and
lower (1205Lu) ASC among metastatic cells, in the subse-
quent experiments.
ASC overexpression in metastatic melanoma has little effect on
cell viability despite its killing effects on primary melanoma
Because ASC expression was higher in primary melanoma
than in metastatic melanoma, we hypothesized that ASC
overexpression may induce growth suppression in human
melanoma. 1205Lu and HS294T cells were transfected with
an ASC expression plasmid. Successful transfection was
confirmed by an increase in ASC mRNA (11.3-fold increase
in 1205Lu cells and 3.7-fold increase in HS294T cells; Figure
1c) and protein (Figure 1d) expression. Overexpression of
ASC induced no significant change in cell viability in 1205Lu
and HS294T cells (Figure 1e); however, it reduced cell
viability in primary melanoma cells (Figure 1f).
ASC knockdown reduces cell viability and inhibits tumor
growth in metastatic melanoma
To investigate the role of ASC on tumor growth, we knocked
down ASC expression by transducing ASC short hairpin RNA
(shRNA) into HS294T and 1205Lu cells. Successful transduc-
tion was confirmed by a decrease in ASC mRNA (84%
reduction in 1205Lu cells and 95% reduction in HS924T cells)
and protein expression in 1205Lu and HS294T cells compared
with their control cells (Figure 2a). Silencing ASC reduced cell
viability in 1205Lu cells (32% reduction) and HS294T cells
(38% reduction) (Figure 2b). G1 cell cycle arrest was induced
in both cells (Figure 2c) and increased cell death was observed
in 1205Lu cells after ASC knockdown (Figure 2d). We then
determined whether the same effect can be observed in vivo.
Nude mice were injected with 1205Lu-control-shRNA cells or
1205Lu-ASC-shRNA cells, and tumor growth was monitored.
Mice injected with 1205Lu-ASC-shRNA cells showed slower
tumor growth and decreased tumor volume (60% reduction on
day 25) compared with the mice injected with 1205Lu-
control-shRNA cells (Figure 2e). Tumor tissues from mice
injected with 1205Lu-ASC-shRNA cells exhibited decreased
mitosis (arrows), proliferation (Ki-67-positive cells), and
angiogenesis (CD31-positive cells) compared with control
tumors (Figure 2f). These results indicate that ASC promotes
tumor growth in metastatic melanoma.
ASC knockdown increases cell viability and enhances tumor
growth in primary melanoma
To investigate the role of ASC in primary melanoma, we
knocked down ASC expression in WM35 and WM115 cells.
Successful transduction was confirmed by a decrease in ASC
mRNA (87% reduction in WM35 and 60% reduction in
WM115) and protein expression (Figure 3a). In contrast with
metastatic melanoma cells, however, silencing ASC in
primary melanoma cells enhanced cell viability (1.7-fold in
WM35 and 1.6-fold in WM115; Figure 3b). Cell proliferation
was enhanced in WM35 cells (Figure 3c) and cell death was
decreased in both WM35 and WM115 cells after ASC
knockdown (Figure 3d). Tumors from WM35-ASC-shRNA
cells grew in mice after day 30, whereas those from WM35-
control-shRNA cells remained small in mice (Figure 3e).
Histological analysis revealed enhanced proliferation (Ki-67-
positive cells) and angiogenesis (CD31-positive cells) in
tumor tissues from WM35-ASC-shRNA cells compared with
those from WM35-control-shRNA cells (Figure 3f). Taken
together, these results suggest that ASC has differential effects
on primary and metastatic melanoma cells: ASC inhibits
tumor growth in primary melanoma cells, whereas it promotes
tumorigenesis in metastatic melanoma cells.
ASC knockdown impairs inflammasome-mediated caspase-1
activation in primary and metastatic melanoma
As an integral component of inflammasome, ASC has an
important role in caspase-1 activity and IL-1b secretion. To
examine inflammasome function, we measured both IL-1b
synthesis and secretion in primary (WM35 and WM115) and
metastatic (HS294T and 1205Lu) melanoma cells after ASC
knockdown (Figure 4a). Consistent with a previous report
(Okamoto et al., 2010), the amount of IL-1b synthesized in
WM35 and WM115 was very low (just above the limit of
sensitivity) and IL-1b secretion was not detected in these
primary melanoma cells (o3pgml1). In all four cells
transduced with ASC shRNA, IL-1b synthesis was not
changed relative to control cells (Figure 4a). However, IL-
1b secretion was significantly decreased in metastatic
melanoma cells transduced with ASC shRNA (62% reduction
in HS924T-ASC-shRNA cells and 46% reduction in 1205Lu-
ASC-shRNA cells; Figure 4a). Consistent with these results,
activated caspase-1 (20-kDa fragments) was decreased in all
cells transduced with ASC shRNA (Figure 4b). Caspase-1
activity was also decreased in these cells (78, 73, 85, and
88% reduction in WM35-ASC-shRNA, WM115-ASC-shRNA,
HS294T-ASC-shRNA, and 1205Lu-ASC-shRNA cells, respec-
tively; Figure 4c), indicating that ASC knockdown impairs
inflammasome-mediated caspase-1 activation in both pri-
mary and metastatic melanoma cells.
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ASC knockdown decreases NF-jB activity in metastatic
melanoma but increases the activity in primary melanoma
Through its PYD or CARD, ASC can associate with PYD- or
CARD-containing proteins. In particular, ASC has been
shown to mediate signals by upregulating or downregulating
NF-kB (Stehlik et al., 2002; Hasegawa et al., 2005; Sarkar
et al., 2006). To assess the association of ASC and NF-kB, we
first measured NF-kB activity after ASC knockdown by
luciferase assay. Although NF-kB activity was increased in
primary melanoma cells (10.9-fold in WM35 and 7.3-fold in
WM115), it was decreased in metastatic melanoma cells
(72% reduction in HS294T and 64% reduction in 1205Lu)
after ASC knockdown (Figure 5a). To further decipher the role
of ASC on NF-kB activity in melanoma cells, we examined
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Figure 1. Effects of Apoptosis-associated Speck-like protein containing a CARD (caspase recruitment domain) (ASC) expression in melanoma cells.
(a) Representative staining of human melanoma tumors with ASC. Bar¼ 100mm. Arrows depict melanoma cells. (b) Western blot of ASC in human melanoma
cell lines. b-Actin served as a loading control. (c) Quantitative RT-PCR (qRT-PCR) of ASC after transfection with pCMV-GFP-V empty vector (pCMV-V) or
pCMV-GFP-ASC vector (pCMV-ASC). Expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (d) Western blot of cells
transfected with pCMV-V or pCMV-ASC. Anti-ASC antibody detects both transfected (depicted as GFP-ASC) and endogenous ASC. b-Actin served as a loading
control. (e) Cell viability in 1205Lu and HS294T transfected with pCMV-V or pCMV-ASC. (f) Cell viability in WM35 and WM115 after 48 hours of transfection
with pCMV-V or pCMV-ASC. Data represent mean±SE (n¼ 3). ***Pp0.001 compared with transfection with pCMV-V. OD, optical density.
520 Journal of Investigative Dermatology (2013), Volume 133
W Liu et al.
Dual Role of ASC in Human Melanoma Cells
proteins involved in the NF-kB activation pathway. Immu-
noprecipitation revealed the interaction of ASC with IkB
kinase (IKK)a/b in both primary (WM35) and metastatic
(1205Lu) cells (Figure 5b, 1st and 3rd panels immunoblotted
with ASC). Whereas interaction of ASC and IKKa/b
was reduced after ASC knockdown (Figure 5b, 1st and 3rd
panels), the expression of IKKa/b was not changed in the
melanoma cells transduced with ASC shRNA (Figure 5b,
2nd and 4th panels; Figure 5c, 2nd panels). Phosphorylated
IKKa/b expression, on the other hand, was increased in
WM35 cells and decreased in 1205Lu cells after ASC
knockdown (Figure 5c, 3rd panels). Consistent with these
results, IkBa expression was decreased in WM35 cells
and increased in 1205Lu cells after ASC knockdown
(Figure 5c, 4th panels). The findings in IkBa expression were
further confirmed in xenografted tumor tissues derived from
these cells (Figure 5d). The results indicate that ASC inhibits
NF-kB activity in primary melanoma cells by suppressing
IKKa/b phosphorylation and inhibiting IkB degradation. On
the contrary, ASC increases IKKa/b phosphorylation and IkB
degradation and enhances NF-kB activity in metastatic
melanoma cells.
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Figure 2. Effects of Apoptosis-associated Speck-like protein containing a CARD (caspase recruitment domain) (ASC) short hairpin RNA (shRNA) on metastatic
melanoma. (a) Quantitative RT-PCR (qRT-PCR) (left panel) and western blot (right panel) of ASC in cells transduced with control or ASC shRNA. mRNA
expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). b-Actin served as a loading control. (b) Cell viability in cells
transduced with shRNA. (c) Cell cycle analysis in cells transduced with control and ASC shRNA. (d) Annexin-V/propidium iodide (PI) staining in cells transduced
with control and ASC shRNA. (e) Effects of ASC knockdown in vivo. Nude mice injected with 1205Lu-control-shRNA or 1205Lu-ASC-shRNA cells (upper panel).
Tumor growth curve (lower panel). (f) Representative tumor sections stained with hematoxylin and eosin (H&E) (upper panel), Ki-67 (middle panel), and CD31
(lower panel). Bar¼ 100 mm. Data represent mean±SE (n¼ 3 except in e, and n¼8 in e). **Po0.01; ***Po0.001. OD, optical density.
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ASC knockdown decreases IL-1 receptor signaling–dependent
activation of NF-jB in metastatic melanoma
Previously, we have shown a positive feedback loop of IL-1
receptor (IL-1R) signaling through secreted IL-1b in metastatic
melanoma cells (Okamoto et al., 2010). IL-1R signaling
activates the NF-kB pathway. Therefore, to examine the role
of ASC on NF-kB in human melanoma cells, we investigated
IL-1R signaling. IL-1a was used to stimulate IL-1R signaling,
whereas an IL-1 receptor antagonist was used to inhibit a
positive feedback loop. Primary melanoma cells (WM35) did
not respond to the stimulation by IL-1a unless ASC is silenced
(Figure 5e, 1st vs. 2nd bars and 4th vs. 5th bars), indicating
that IL-1R is functional, but IL-1R signaling is impaired by
ASC in primary melanoma. In contrast, in metastatic
melanoma cells (1205Lu) with ASC knockdown, IL-1a
treatment rescued the suppressed NF-kB activity to the same
level as that in 1205Lu-control-shRNA cells (Figure 5f, 2nd
vs. 5th bars), suggesting that IL-1R signaling in metastatic
melanoma is functional despite the ASC knockdown. How-
ever, treatment with IL-1 receptor antagonist did not reduce
NF-kB activity in 1205Lu-ASC-shRNA cells relative to their
controls (Figure 5f, 4th vs. 6th bars in 1205Lu-ASC-shRNA
cells and 1st vs. 3rd bars in 1205Lu-control-shRNA cells),
suggesting that IL-1-mediated IL-1R stimulation is already
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inhibited by ASC knockdown in metastatic melanoma. Taken
together, these results indicate that ASC suppresses IL-1R
signaling by inhibiting NF-kB activation in primary melano-
ma cells, whereas it contributes to an inflammasome-
mediated positive feedback loop of IL-1R signaling in
metastatic melanoma cells.
DISCUSSION
Previous studies have indicated ASC as a tumor suppressor
gene that induces apoptosis in certain tumor cell lines. This
study demonstrates, however, that although ASC suppresses
tumor growth in primary melanoma, it promotes the growth
of metastatic melanoma.
ASC contains PYD and CARD, and is thus a central
adaptor protein to recruit PYD-containing NLRP3 to CARD-
containing pro-caspase-1 for inflammasome activation and
subsequent processing of IL-1b. We have previously shown
the coexpression of ASC and NLRP3 in human melanoma
cells and demonstrated that constitutively activated inflam-
masomes are present in both primary and metastatic
melanoma (Okamoto et al., 2010). Congruent with our
previous findings, ASC knockdown was shown here to
decrease caspase-1 activity and impair IL-1b processing/
secretion in human melanoma cells.
Only metastatic melanoma cells, however, spontaneously
produce and secrete high levels of IL-1b, resulting in
angiogenesis and tumor promotion (Okamoto et al., 2010).
A previous report has shown that ASC can either inhibit or
activate NF-kB, depending on the cellular context (Stehlik
et al., 2002). Consistent with this, we found dual roles of ASC
in human melanoma cells. Although ASC is necessary for
inflammasome function and maturation of IL-1b in human
melanoma, ASC differentially regulates NF-kB activity in
primary and metastatic melanoma. NF-kB is pivotal for
transactivation of cell cycle regulation, cytokine production,
and expression of adhesion molecules, and is dysregulated
in many cancers (Van Waes, 2007). We show here that ASC
downregulates NF-kB activity in primary melanoma cells,
despite the coexpression of ASC and NLRP3. In metastatic
melanoma cells, however, NF-kB activity is enhanced by
ASC. These seemingly contradictory functions of ASC may
depend on the cellular context (primary vs. metastatic)
(Figure 6). For example, ASC expression in primary melano-
ma cells inhibits NF-kB activity by inhibiting IKK-mediated
degradation of IkB. This may explain why primary melanoma
cells do not secrete IL-1b despite constitutively assembled
and activated inflammasomes. On the other hand, the
inhibitory effect of ASC on NF-kB is diminished in metastatic
melanoma. As ASC associates with multiple PYD- and
CARD-containing proteins, it is tempting to speculate that
decreased ASC expression in metastatic melanoma cells may
result in competition among various pathways for a limited
supply of ASC protein. However, overexpressing ASC in
metastatic melanoma cells did not alter NF-kB activity
(Supplementary Figure S2a online), suggesting that constitu-
tively active IL-1R signaling and NF-kB activity in metastatic
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melanoma (autoactive Signal 1) make cells less vulnerable to
the inhibitory effect of ASC on NF-kB. It is noteworthy that
overexpressing ASC in metastatic melanoma cells did not
affect autocrine IL-1b secretion (Supplementary Figure S2b)
or caspase-1 activity (Supplementary Figure S2c), suggesting
that there is enough biologically functional ASC to mediate
caspase-1-dependent maturation and secretion of IL-1b, and
the inflammasome is constitutively active in metastatic
melanoma (autoactive Signal 2), resulting in a positive
feedback mechanism of IL-1 signaling to further upregulate
NF-kB activity in the absence of the inhibitory effect of ASC
on IkB. ASC may thus contribute to a positive feedback loop
of autoinflammation in metastatic melanoma, in which
upregulated NF-kB induces transcription of pro-IL-1b, which
is subsequently processed and secreted by constitutively
active inflammasome, leading to further NF-kB activation
through autocrine IL-1 signaling. Alterations in ASC and
associated protein interactions may thus result in varying
tumor-dependent responses, implying that ASC could be a
promising therapeutic target in metastatic cancers.
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or IL-1 receptor antagonist (IL-1Ra) (10mgml1) for 24 hours. Data represent mean±SE (n¼ 3). **Po0.01; ***Po0.001 compared with cells transduced with
control shRNA.
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In conclusion, ASC appears to have cell-dependent
roles in tumor pathogenesis by differentially regulating NF-
kB activity and IL-1b processing. In metastatic melanoma,
ASC induces tumorigenic pathways, most likely by activating
caspase-1-dependent IL-1b secretion and enhancing auto-
inflammatory NF-kB activity. On the other hand, higher
levels of ASC expression in primary melanoma reduce
IKKa/b phosphorylation and inhibit NF-kB activity. In fact,
it appears that ASC transforms from a protein with antitumor
properties in primary melanoma to a protumorigenic
factor in metastatic melanoma. To our knowledge, no
previous studies have examined stage-dependent roles of
ASC in cancer cells. Further studies of ASC and its upstream
and downstream intermediaries may enhance our under-
standing of the molecular mechanisms governing tumorigenesis
and reveal new molecular targets for designing anti-
cancer drugs.
MATERIALS AND METHODS
Cell culture
Human melanoma cell lines were obtained from the American Type
Culture Collection (Manassas, VA): WM1552c and WM35 are from
radial growth phase primary melanoma; WM115, WM75, and
WM278 are from vertical growth phase primary melanoma; and
A375, WM852c, HS294T, and WM1617 are from metastatic
melanoma. 1205Lu is from a lung metastasis after subcutaneous
injection of mice with a primary melanoma line WM793. Cells were
maintained in RPMI 1640 (Mediatech, Manassas, VA) (except
HS294T) or Dulbecco’s modified Eagle’s medium (Mediatech)
(HS294T), supplemented with 10% fetal bovine serum (Mediatech),
100mgml1 streptomycin, and 100Uml1 penicillin (Mediatech).
Western blotting analysis
Western blotting analysis was carried out as described previously
(Okamoto et al., 2010). Anti-caspase-1, IkKa/IkKb, phospho-IkKa/
IkKb, and IkBa antibodies were from Cell Signaling Technology
(Boston, MA). Anti-ASC antibody was from Alexis Biochemicals (San
Diego, CA). Horseradish peroxidase–conjugated anti-mouse IgG was
from Jackson Immuno-Research Laboratories (West Grove, PA), and
horseradish peroxidase–conjugated anti-rabbit IgG and anti-goat IgG
were from Sigma-Aldrich (St Louis, MO). Signals were detected by
SuperSignal West Femto maximum Sensitivity Substrate (Thermo
Scientific, Rockford, IL) and analyzed using GelDoc 200 (Bio-Rad,
Hercules, CA).
DNA transfection
Plasmid pCMV-GFP-ASC or pCMV-GFP empty Vector (OriGene
Technologies, Rockville, MD) was transfected at a concentration of
0.5 mgml1 by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
After 48 hours, cells were collected and analyzed.
RNA extraction and quantitative RT-PCR analysis
RNA was extracted using the RNAqueous-Micro kit (Ambion,
Austin, TX) and reverse transcribed. Quantitative PCR was
performed with Power SYBR Green PCR Master Mix (Applied Bio-
systems, Foster City, CA) on the MX3000P PCR system (Stratagene,
La Jolla, CA). Primers were designed to generate a PCR product of 50
to 150 bp. The following primer sequences were used: human ASC,
forward: 50-CATGAACTGATCGACAGGATG-30, reverse: 50-GGAC
CTCCTCCAAATGTTTC-30; human GAPDH, forward: 50-CAGGGCT
GCTTTTAACTCTGG-30, reverse, 50-TGGGTGGAATCATATTGGAA
CA-30.
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Figure 6. Hypothetical roles of Apoptosis-associated Speck-like protein containing a CARD (caspase recruitment domain) (ASC) in melanoma tumor
progression. Solid lines indicate constitutive/autonomous pathways. Dashed lines indicate signal-dependent pathways. Arrow thickness indicates the relative
strength of signaling pathways. ASC inhibits phosphorylation of IkB kinase (IKK)a/b and decreases NF-kB in primary melanoma cells. Synthesis of pro-IL-1b is
thus low and IL-1b secretion is minimal despite autoactive inflammasome in primary melanoma cells. In metastatic melanoma, however, autoactive IL-1R
signaling and other signaling pathways result in reduced inhibition of NF-kB from ASC in the presence of sustained autoactive inflammasome, leading to the
spontaneous synthesis and secretion of IL-1b from melanoma cells. IL-1b secreted from melanoma cells further augments the autoinflammatory loop of
metastatic melanoma cells to activate NF-kB. NLRP, NOD-like receptor family containing pyrin domain.
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Cell viability assay
Cell viability was measured using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay kit (Promega, Madison, WI).
A total of 1–5 103 cells in 100ml of media were plated per well
in 96-well plates and cultured. Viability was determined using
the ELX808 Ultra Microplate Reader (Bio-Tek Instruments,
Winooski, VT).
shRNA transduction
Cells were transducted with shRNA lentiviral particles against
control or ASC (Santa Cruz Biotechnology, Santa Cruz, CA) in cell
culture medium containing 5mgml1 of Polybrene (Santa Cruz
Biotechnology). After overnight transduction, cells were incubated
in medium with 1mgml1 of puromycin (Santa Cruz Biotechnology)
to select for stable clones expressing transduced shRNA, and
maintained in medium with 1 mgml1 of puromycin at 37 1C.
Cell cycle analysis
Cells were stained at 4 1C with Krishan’s staining buffer containing
70 mM propidium iodide (Sigma-Aldrich), 3.8mM trisodium citrate
(Sigma-Aldrich), 0.01% Nonidet P-40 (Sigma-Aldrich), and 0.01mg
of RNase A (Roche Diagnostics, Indianapolis, IN), and analyzed
using flow cytometer FC500 (Beckman-Coulter, Brea, CA). The
Modfit LT program (Verity Software House, Topsham, ME) was used
for data analysis.
Dead cell apoptosis assay
Cells were stained with Annexin-V and propidium iodide (Invitro-
gen) following the manufacturer’s instructions for flow cytometric
analysis. Cell death was measured from apoptotic (Annexin-V-
positive) and/or necrotic (PI-positive) cells.
Immunohistochemistry
Human melanoma tissues were obtained from surgical specimens
with written consent from the patients under institutional
review board–approved protocols, adhering to Health Insurance
Portability and Accountability Act regulations and to the Declaration
of Helsinki Principles. Paraffin sections were treated with a
low pH solution such as citrate buffer (pH 6) (Leica Microsystems,
Baffalo Grove, IL). ASC and IkBa were stained with rabbit anti-
human ASC (Proteintech Group, Chicago, IL) and rabbit anti-human
IkBa (Abcam, Cambridge, MA), respectively, followed by rat anti-
rabbit IgG link (DAKO, Carpinteria, CA) and Bond Polymer
Refine Red Detection kit (Leica Microsystems). CD31 was stained
with rat anti-mouse CD31 (Dianova, Rodeo, CA) and rabbit
anti-rat IgG link (DAKO), followed by detection with the Bond
Polymer Refine Red Detection kit. Ki-67 was stained with rabbit
anti-human Ki-67 (Thermo Scientific) and rat anti-rabbit IgG
link, followed by detection with the Bond Polymer Refine
Detection kit (Leica Microsystems). Sections were counterstained
with hematoxylin (Leica Microsystems), and were reviewed by two
observers.
Tumor formation in nude mice
The 6-week-old female athymic nu/nu mice (Jackson Laboratory, Bar
Harbor, ME) were used. Animals were kept under specific pathogen-
free conditions, according to National Institutes of Health Animal
Care Guidelines. Experimental protocols were approved by the
Institutional Animal Care and Use Committee of University of
Colorado Denver. A total of 1 106 1205Lu-control-shRNA or
1205Lu-ASC-shRNA cells or 2.5 106 WM35-control-shRNA or
WM35-ASC-shRNA were resuspended in 0.1ml of Matrixgel Base-
ment Membrane Matrix (BD Biosciences, San Jose, CA) diluted 1:1
with phosphate-buffered saline and injected intradermally into the
flank of mice. Tumor growth was monitored bi-weekly with an
electronic digital caliper (Control, Friendswood, TX). Tumor volume
was calculated by the following formula: tumor volume¼ (longest
diameter) (shortest diameter)2/2.
ELISA
Human IL-1b ELISA kit was obtained from R&D Systems (Minnea-
polis, MN) (Okamoto et al., 2010). A total of 1 105 per ml of cells
were seeded in 6-well plates, and the medium was changed to
OptiMEM (Invitrogen) when cells reached 80% confluence. After
24 hours, supernatants were collected to assess secreted IL-1b.
Intracellular cytokines were assessed by lysing cells with 0.5% Triton
X-100 in phosphate-buffered saline followed by the freeze–thaw
cycle.
Caspase-1 activity assay
Caspase-1 Flica kit (ImmunoChemistry Technologies, LLC, Bloo-
mington, MN) was used. Cells (1.5 105/100ml per well in 96-well
plates) were trypsinized, washed in ice-cold phosphate-buffered
saline, and incubated with caspase-1 inhibitor probe (FAM-YVAD-
FMK) for 1 hour at 37 1C, 5% CO2. The fluorescence was measured
using the fluorescence plate reader (Promega). A recombinant
caspase-1 was used as a positive control.
NF-jB activity assay
The Ready-to-Glow Secreted Luciferase pNFkB-MetLuc
Vector Kit (Clontech Laboratories, San Francisco, CA) was
used. A total of 5 103 per ml of melanoma cells were seed in a
24-well plate, transfected with a control vector (pMetLuc2-Reporter)
or an NF-kB vector (pNFkB-MetLuc2 Reporter) in OptiMEM, and
treated with IL-1a (10 ngml1) and/or IL-1 receptor antagonist
(10 mgml1). The cell culture supernatant was collected 24 hours
later, and luciferase activity was measured using a luminometer
(Promega).
Immunoprecipitation and immunoblot analysis
Immunoprecipitation was carried out as described previously
(Okamoto et al., 2010). Briefly, cell lysates were incubated with
primary antibodies or preimmune serum and immunoprecipitated
with protein A/G plus agarose (Santa Cruz Biotechnology). The
precipitates were washed, separated by SDS-PAGE, and analyzed
with western blotting.
Statistical analysis
The values in the figures are expressed as the means±SE. The figures
in this study are representatives of more than two different
experiments. Statistical analysis of the data between two groups
was performed by a Student’s t-test. Values of Po0.05 were
considered as statistically significant.
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